Diseases of large granular lymphocytes

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Large granular lymphocyte (LGL) leukemias are rare lymphoproliferative malignancies.
• These arise from mature T-cell (CD3+) or natural killer (NK)-cell (CD3-) lineages.
• LGL diseases exhibit a spectrum of biologic behavior, from indolent to aggressive.

Purpose of the Study:

• To review four distinct LGL diseases: indolent T-cell LGL leukemia, aggressive T-cell LGL leukemia, chronic NK-cell leukemia, and aggressive NK-cell leukemia.
• To present an up-to-date systematic review of therapies for each LGL leukemia entity.

Main Methods:

• Systematic review of existing literature on LGL leukemia subtypes and their therapies.
• Analysis of key features distinguishing indolent from aggressive LGL leukemia.
• Evaluation of current and emerging therapeutic strategies.

Main Results:

• Distinguishing features include sustained LGLs, immunophenotype, clonal origin, and clinical presentation.
• Indolent T-cell or NK-cell LGL leukemia is typically managed with immunosuppressive therapies.
• Aggressive T-cell and NK-cell LGL leukemia require intensive chemotherapy induction regimens.
• Novel targeted therapies, including monoclonal antibodies and small molecules, are under investigation.

Conclusions:

• Further research into molecular pathogenic mechanisms is crucial.
• Development of targeted therapies tailored to distinct LGL leukemia entities is needed.
• Advancements in understanding and treating LGL leukemias are expected to improve patient outcomes.